Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptome-wide expression analysis of wild-type p53 and PANDAs in p53-null HCT116 cells

ABSTRACT: Transcriptome-wide expression analysis of wild-type p53 and PANDAs in p53-null HCT116 cells

PROVIDER: PRJNA850429 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR19737227_1.fastq.gz	Fastqsanger.gz
	SRR19737227_2.fastq.gz	Fastqsanger.gz
	SRR19737228_1.fastq.gz	Fastqsanger.gz
	SRR19737228_2.fastq.gz	Fastqsanger.gz
	SRR19737229_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 8

Similar Datasets

The DNA binding selectivity by wild-type p53 and PANDAs

Project description:We performed ChIP-seq analysis of p53-null HCT116 cells stably expressed wild-type p53 or mutant p53 followed by ATO treatment (PANDAs) to identify p53 binding characteristics by wild-type p53 and PANDAs.

2024-01-31 | GSE195622 | GEO

Transcriptome-wide expression analysis of wild-type p53 and PANDAs in p53-null HCT116 cells

Project description:Our RNA-seq data suggested the different transcriptional profiles of wild-type p53 and PANDAs treated with or without ATO.

2024-01-31 | GSE206395 | GEO

Identification of p53-regulated genes in wild-type p53 or p53-null HCT116 cells

Project description:Identification of p53-regulated genes in wild-type p53 or p53-null HCT116 cells

| PRJNA517505 | ENA

Identification of p53-regulated genes in wild-type p53 or p53-null HCT116 cells

Project description:Microarray-based gene expression analysis of HCT116 p53+/+ and HCT116 p53−/− treated with doxorubicin to activate p53 in time-dependent manner.

2019-01-29 | GSE125787 | GEO

Gene expression profiling of CYC116 and ZM447439 resistant HCT116 wild type and HCT116 p53 null clones in comparison to parent cell lines

Project description:HCT116 and HCT116 p53 null were exposed to two Aurora kinase inhibitors (CYC116 and ZM447439) at cytotoxic concentrations. Within 4-5 weeks we were able to select and isolate 10 drug resistant clones from each group. 3 clones were selected for gene expression profiling using Affymetrix microarrays (Human Gene 1.0 ST Array). The samples in each group were initially given the code names as follows. Group 1. [R1.3, R4.2, R6.3: CYC116 p53 wild type], Group 2. [R8.7, R9.7, R10.7:CYC116 p53 null], Group 3. [R7.1, R15.1, R16.1:ZM447439 p53 wild type], and Group 4. [R1.5, R3.5, R4.5:ZM447439 p53 null). For publication purpose the names were later changed to, Group 1. [R1.1, R1.2, R1.3: CYC116 p53 wild type], Group 2. [R2.1, R2.2, R2.3:CYC116 p53 null], Group 3. [R3.1, R3.2, R3.3:ZM447439 p53 wild type], and Group 4. [R4.1, R4.2, R4.3:ZM447439 p53 null].

2012-04-01 | E-MEXP-3526 | biostudies-arrayexpress

Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246

Project description:exosomes isolated from: HT29+control shRNA; HT29+p53 shRNA; HCT116 WT p53; HCT116 mutant p53; HCT116 null p53; media used as negative control

2018-02-09 | MSV000082047 | MassIVE

Identification of a STAT2 transcriptome in HCT116 p53 null tumor xenografts

Project description:Identification of a STAT2 transcriptome in HCT116 p53 null tumor xenografts

| PRJNA564684 | ENA

RNAseq expression of p53-null and p53-null/PLK2-null mammary tumors

Project description:RNAseq expression of p53-null and p53-null/PLK2-null mammary tumors

| PRJNA731110 | ENA

Transcription profiling by array of human colorectal cancer epithelial (HCT116) p53 null cells treated with SN38 for 6, 12 and 24h

Project description:HCT116 p53 null cells were treated with 5nM SN38 (active metabolite of CPT-11) for 6, 12 and 24h. Following this RNA was harvested for transcriptional profiling.

2007-11-30 | E-MEXP-1194 | biostudies-arrayexpress

The DNA binding selectivity by wild-type p53 and PANDAs

Project description:The DNA binding selectivity by wild-type p53 and PANDAs

| PRJNA801502 | ENA